Global Antiviral Drugs Market Size to exhibit a CAGR of 2.5% by 2025; Major players Bristol Myers Squibb (U.S.), Gilead Sciences (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (U.S), Aurobindo Pharma Limited (India) to lead the global market share in terms of revenue.

The global antiviral drugs market size was USD 55.91 billion in 2019 and is projected to reach USD 64.9 billion by 2025, registering a CAGR of 2.5% during the forecast period.

This global report by iCognition Insights provides a detail market analysis of the antiviral drugs market by Drug Class (Reverse Transcriptase Inhibitors, DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), by Type (Generic, Branded), by Application (Hepatitis, HIV, Influenza, Herpes), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Rise in the number of cases of viral infections such as hepatitis, influenza, coronavirus, and human immunodeficiency virus (HIV) is a key driver for the growth of this market.

Download sample copy of this report: https://www.icognitioninsights.com/product/antiviral-drugs-market-analysis-by-drug-class/

COVID-19 impact and deviation analysis: This report includes an exclusive section on the COVID-19 impact and deviation analysis with in-depth insights on prevalence, key market trends and market size deviation analysis (2020-2025). Our domain experts combined with experienced market analysts take continuous efforts to discover contextually relevant insights from the data to provide you structured and reliable insights and help you sustain and sail through the pandemic wave.

Reach us to learn more about how we can help you prepare for the future: https://www.icognitioninsights.com/contact/

In 2019, the reverse transcriptase inhibitors segment commanded the maximum revenue share.

Based on the research by iCognition Insights research and analysis experts, the reverse transcriptase inhibitors segment will continue to grow at the faster CAGR followed by the DNA polymerase inhibitors segment which is expected to see a significant growth during the forecast period till 2025.

Rising consumer perception towards high quality branded medicines to drive the growth for branded antiviral drugs.

In 2019, based on type, the branded segment accounted for the maximum revenue share owing to the rising consumer perception towards this segment. However, generics antiviral drugs segment is anticipated to show an accelerated growth due to the increasing awareness about the benefits associated with the adoption of generic medicine.

Hepatitis application segment to dominate the market during the forecast period.

Increasing prevalence and incidences of varied types of hepatitis is set to drive the market. Moreover, the antiviral drugs market is also set to gain momentum from HIV segment owing to its large patient base worldwide.

Asia-Pacific is projected to record the fastest CAGR over the forecast period.

Rising prevalence of viral infections, improving healthcare sector & policies, and active research & development engagements will foster the growth in the Asia-Pacific region. The North America market is expected to maintain the largest share of the global market, attributed by the advanced healthcare infrastructure, presence of large number of pharmaceutical & biotechnology firms, and rising awareness initiatives by government.

Learn more about the key questions addressed in this decision-intelligence report: https://www.icognitioninsights.com/product/antiviral-drugs-market-analysis-by-drug-class/#1609849655948-15082c58-b100

Key market players: Bristol Myers Squibb (U.S.), Gilead Sciences, Inc. (U.S.), Cipla Limited (U.S.), F. Hoffmann-La Roche AG (Switzerland), Aurobindo Pharma Limited (India), AbbVie Inc. (U.S.), Dr. Reddy’s Laboratories (India), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), and GlaxoSmithKline plc (U.K.).

Research Methodology: All the decision-intelligence reports are developed by implementing proprietary domain-assisted cognition (DAC) research framework that combines gathering precise market information via primary and secondary research, discovering context and relevance, data analysis, quality audit and insights discovery.

Choose from the range of license type that suits best to your business requirement: https://www.icognitioninsights.com/select-license-7/

1. Research Methodology
2. Market Summary
3. Market Dynamics
4. Industry Outlook
5. Covid-19 Impact and Deviation Analysis
6. Antiviral Drugs Market Size and Forecast, by Drug Class (2017-2025), USD Million
   • Reverse Transcriptase Inhibitors (RTI)
   • DNA Polymerase Inhibitors (DPI)
   • Neuraminidase Inhibitors (NI)
   • Protease Inhibitors (PI)
   • Others
7. Antiviral Drugs Market Size and Forecast, by Drug Type (2017-2025), USD Million
   • Branded
   • Generics
8. Antiviral Drugs Market Size and Forecast, by Application (2017-2025), USD Million
   • Hepatitis
   • HIV
   • Influenza
   • Herpes
   • Others
9. Regional Analysis (2017-2025), USD Million
   • North America (U.S., Canada)
   • Europe (Germany, UK, France, Italy, Spain, Russia, Rest of Europe)
   • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
   • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
   • Middle East & Africa (South Africa, Saudi Arabia, Rest of MEA)
10. Competitor Analysis
11. Company Profiles

About iCognition Insights:

iCognition Insights is a global market intelligence and market research services firm, specialized in providing industry-standard syndicated reports and consulting services to global clients across life sciences and healthcare industry verticals. Our methodological research approach coupled with deep domain and analytical expertise opens the doors to the insights that really matter.

With over 20+ years of combined industry experience, we assist our clients in chalking their strategic growth plans and make informed business decisions. Our proprietary research and analysis framework enables our clients discover hidden insights and granular quantitative and qualitative information on the market, technology, or company of interest.

Contact Us:

iCognition Insights

U.S: +1 617 676 0160

APAC: +81 503 196 4844

Email: info@icognitioninsights.com